Abstract: Prostate cancer is a common tumor in men.Androgen receptor (AR) is an essential substance for androgen to bind to prostate cancer cells, exert hormone biological activity, and promote the growth of prostate cancer tissue.At present, AR antagonists are the main therapeutic drugs for prostate cancer.The second-generation AR antagonists such as enzalutamide have been approved with much attention from the market.This paper reviews the research progress of AR antagonists for the treatment of prostate cancer, and analyzes their market sales.